Clinical trial
A Longitudinal Cohort Study of Aplastic Anemia Across the Disease Course
NCT07930793 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Recruiting, started January 2012. Observational study, 9,999 participants (estimated). Lead sponsor Institute of Hematology & Blood Diseases Hospital, China; China. Primary measures: Hematologic response; Clonal evolution and 1 more.
How it compares
68 similar trials: same condition (Anemia, Aplastic) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Longitudinal Cohort Study of Aplastic Anemia Across the Disease Course
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- January 1, 2012
- Completion date
- December 31, 2070
- Enrollment
- 9,999 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: aplastic anemia, clonal hematopoiesis, immunosuppressive therapy
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Healthy volunteers
- No
- Study type
- Observational
- Sites
- 1
- Countries
- China
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| TRACE-AA | A combined retrospective and prospective observational follow-up | |
Show registry wording1. Describe real-world treatment patterns and clinical outcomes in AA, including IST, HSCT, and other therapies.
| ||
Primary endpoints
Registered primary outcome measures; 3 primary.
| Measure | Time frame |
|---|---|
| Hematologic response | Assessments will be conducted at baseline, 6 months, 12 months, and 24 months after treatment, as well as at study completion, with an average interval of approximately 1 year. |
Show registry wordingHematologic response contains improvements in hemoglobin level, platelet count and neutrophil count. | |
| Clonal evolution | Assessments will be conducted at baseline, 6 months, 12 months, and 24 months after treatment, as well as at study completion, with an average interval of approximately 1 year. |
Show registry wordingProgression to paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, or acute myeloid leukemia. | |
| Treatment related adverse events | Within 10 years after allo-HSCT; within 6 months after IST |
Show registry wordingThe main treatment modalities include allogeneic hematopoietic stem cell transplantation (allo-HSCT) and intensive immunosuppressive therapy (IST). Use Common Terminology Criteria for Adverse Events (CTCAE) Version 6 to assess the adverse event | |
Lead sponsor's other trials
Institute of Hematology & Blood Diseases Hospital, China, most recent start first.
+407 more trials See the organization page
Similar trials
Same condition (Anemia, Aplastic) and phase, most recent start first.
+63 more trials See the condition page